verapamil has been researched along with scopolamine hydrobromide in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (13.04) | 18.7374 |
| 1990's | 3 (13.04) | 18.2507 |
| 2000's | 7 (30.43) | 29.6817 |
| 2010's | 9 (39.13) | 24.3611 |
| 2020's | 1 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Creveling, CR; Daly, JW; Lewandowski, GA; McNeal, ET | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Alvarez-Pedraglio, A; Colmenarejo, G; Lavandera, JL | 1 |
| Bruno-Blanch, L; Gálvez, J; García-Domenech, R | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Bard, B; Carrupt, PA; Martel, S | 1 |
| Du-Cuny, L; Mash, EA; Meuillet, EJ; Moses, S; Powis, G; Song, Z; Zhang, S | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cai, P; Kong, LY; Liu, QH; Wang, XB; Wang, ZM; Wu, JJ; Xu, DQ; Yang, XL | 1 |
| Janowsky, DS; Overstreet, DH; Rezvani, AH | 1 |
| Liu, ZM; Wang, YT | 1 |
| McCann, DJ; Rabin, RA; Winter, JC | 1 |
| Furukawa, K; Nomoto, T; Tonoue, T | 1 |
| Haraguchi, K; Iga, T; Ito, K; Kotaki, H; Sawada, Y | 1 |
| Bankstahl, JP; Bankstahl, M; Ding, XQ; Kuntner, C; Langer, O; Löscher, W; Meier, M; Müller, M; Stanek, J; Wanek, T | 1 |
| Bang, E; Duman, RS; Ghosal, S; Girgenti, MJ; Hare, BD; Lepack, AE; Yue, W | 1 |
| Gu, X; Hu, J; Li, M; Lv, D; Shen, X; Sun, X; Wang, C; Wang, J; Yu, H | 1 |
| Boopathy, R; Kumar, CR; Ponne, S | 1 |
1 review(s) available for verapamil and scopolamine hydrobromide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
22 other study(ies) available for verapamil and scopolamine hydrobromide
| Article | Year |
|---|---|
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Anesthetics, Local; Animals; Batrachotoxins; Calcium Channel Blockers; Cyclic AMP; Guinea Pigs; Histamine H1 Antagonists; In Vitro Techniques; Ion Channels; Neurotoxins; Sodium; Tranquilizing Agents; Tritium | 1985 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Cheminformatic models to predict binding affinities to human serum albumin.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Tricyclic; Chromatography, Affinity; Cyclooxygenase Inhibitors; Databases, Factual; Humans; Hydrophobic and Hydrophilic Interactions; Penicillins; Pharmaceutical Preparations; Protein Binding; Quantitative Structure-Activity Relationship; Reproducibility of Results; Serum Albumin; Steroids | 2001 |
Topological virtual screening: a way to find new anticonvulsant drugs from chemical diversity.
Topics: Anticonvulsants; Computer Simulation; Databases, Factual; Discriminant Analysis; Drug Design; Molecular Structure; Quantitative Structure-Activity Relationship | 2003 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Lipophilicity of basic drugs measured by hydrophilic interaction chromatography.
Topics: Chemistry, Pharmaceutical; Chromatography; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Pharmaceutical Preparations; Solubility; Technology, Pharmaceutical | 2009 |
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
Topics: Antineoplastic Agents; Blood Proteins; Caco-2 Cells; Cell Membrane Permeability; Computer Simulation; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Phosphoproteins; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Quantitative Structure-Activity Relationship | 2009 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Rational modification of donepezil as multifunctional acetylcholinesterase inhibitors for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cell Survival; Cholinesterase Inhibitors; Copper; Donepezil; Drug Design; Humans; Indans; Kinetics; Liver; Mice; Models, Molecular; Peptide Fragments; Piperidines; Protein Aggregates; Protein Conformation | 2016 |
Drug-induced reductions in ethanol intake in alcohol preferring and Fawn-Hooded rats.
Topics: Alcohol Drinking; Alcoholism; Animals; Buspirone; Drinking Behavior; Ethanol; Feeding Behavior; Fluoxetine; Male; Pindolol; Piperazines; Rats; Rats, Inbred Strains; Rats, Wistar; Scopolamine; Self Administration; Serotonin Receptor Agonists; Species Specificity; Verapamil | 1991 |
Morphometric study of neuromuscular junction in rabbits subjected to shock by superior mesenteric artery occlusion.
Topics: Acetylcholinesterase; Adenosine Triphosphate; Animals; Liver; Mesenteric Arteries; Mesenteric Vascular Occlusion; Neuromuscular Junction; Rabbits; Scopolamine; Shock; Verapamil | 1990 |
Use of the radial maze in studies of phencyclidine and other drugs of abuse.
Topics: Animals; Brain; Learning; Lysergic Acid Diethylamide; Memory; Organ Specificity; Phenazocine; Phencyclidine; Scopolamine; Substance-Related Disorders; Verapamil | 1987 |
Transition from neurogenic to myogenic receptivity for thyrotropin-releasing hormone (TRH) in the duodenum of the neonatal rat.
Topics: Acetylcholine; Aging; Animal Population Groups; Animals; Animals, Newborn; Animals, Suckling; Duodenum; Female; Hexamethonium Compounds; In Vitro Techniques; Male; Muscle Contraction; Muscle, Smooth; Rats; Scopolamine; Tetrodotoxin; Thyrotropin-Releasing Hormone; Verapamil | 1981 |
Catalepsy induced by calcium channel blockers in mice.
Topics: Amlodipine; Animals; Binding, Competitive; Calcium Channel Blockers; Catalepsy; Dihydropyridines; Diltiazem; Disease Models, Animal; Flunarizine; Male; Mice; Muscarinic Antagonists; Nitrobenzenes; Piperazines; Predictive Value of Tests; Receptors, Cholinergic; Receptors, Dopamine D1; Receptors, Dopamine D2; Scopolamine; Time Factors; Verapamil | 1998 |
A novel positron emission tomography imaging protocol identifies seizure-induced regional overactivity of P-glycoprotein at the blood-brain barrier.
Topics: Analysis of Variance; Animals; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Calcium Channel Blockers; Carbon Isotopes; Computer Simulation; Disease Models, Animal; Female; Gene Expression Regulation; Heterocyclic Compounds; Magnetic Resonance Imaging; Models, Chemical; Organometallic Compounds; Pilocarpine; Positron-Emission Tomography; Quinolines; Rats; Rats, Sprague-Dawley; Scopolamine; Seizures; Time Factors; Verapamil | 2011 |
Activity-Dependent Brain-Derived Neurotrophic Factor Release Is Required for the Rapid Antidepressant Actions of Scopolamine.
Topics: Animals; Antidepressive Agents; Brain; Brain-Derived Neurotrophic Factor; Calcium Channels, L-Type; Cells, Cultured; Depressive Disorder; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; gamma-Aminobutyric Acid; Male; Mice, Transgenic; Motor Activity; Neurons; Rats, Sprague-Dawley; Receptor, Muscarinic M1; Receptor, trkB; Scopolamine; Synaptosomes; Time Factors; Verapamil | 2018 |
The Requirement of L-Type Voltage-Dependent Calcium Channel (L-VDCC) in the Rapid-Acting Antidepressant-Like Effects of Scopolamine in Mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Calcium Channel Blockers; Calcium Channels, L-Type; Cognitive Dysfunction; Depression; Disease Models, Animal; Hippocampus; Male; Mice; Mice, Inbred C57BL; Nerve Growth Factors; Neuropeptides; Prefrontal Cortex; Scopolamine; Verapamil | 2018 |
Verapamil attenuates scopolamine induced cognitive deficits by averting oxidative stress and mitochondrial injury - A potential therapeutic agent for Alzheimer's Disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Avoidance Learning; Brain; Cell Line, Tumor; Cell Survival; Cognition Disorders; Humans; Male; Membrane Potential, Mitochondrial; Mice; Mitochondria; Neuroprotective Agents; Oxidative Stress; Reactive Nitrogen Species; Reactive Oxygen Species; Scopolamine; Verapamil | 2020 |